Note:This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information.This article is intended solely for the introduction of medications related to medical and health care; it does not constitute a recommendation for treatment plans (if any), nor does it represent the platform’s position.Authorization is required for any article reprints.
On June 3, 2026, CytomX Therapeutics announced the expansion of its collaboration and license agreement with Regeneron Pharmaceuticals. The two companies will jointly develop conditionally activated bispecific cancer therapies by leveraging CytomX’s Probody® therapeutic platform and Regeneron’s Veloci-Bi® bispecific antibody development platform.This collaboration commenced on November 17, 2022. According to the agreement at that time,CytomX will receive a $30 million upfront payment and is eligible for future target nomination payments, as well as up to $2 billion in preclinical, clinical, and commercial milestones.CytomX is also eligible to receive tiered global net sales royalties.Under the expanded agreement, Regeneron and CytomX will continue to collaborate on discovery activities to identify and validate conditionally activated bispecific antibodies. Regeneron will be responsible for funding preclinical and clinical development as well as commercialization activities. CytomX will receive$37 milliontarget nomination fees for the two other selected targets, Regeneron has the right to select up to6 unitsAdditional Future Targets.The total potential nomination payments for expanded collaboration targets, along with preclinical, clinical, regulatory, and commercial milestones, could reach approximately $4 billion.. CytomX is also eligible to receive tiered global net sales royalties on collaborative products.The key feature of CytomX’s Probody therapeutic platform is that the target-binding sites of therapeutics developed using this platform are masked, thereby avoiding toxicity to healthy tissues. However, due to the high concentration of proteases in the tumor microenvironment, these proteases can unmask the previously concealed target-binding sites once the drug reaches the tumor site, activating the drug and enabling it to kill cancer cells. Consequently, such drugs offer a wider therapeutic window and hold potential for combination therapy with many other agents. Many cancer combination therapies fail because the drug combinations exert excessive toxicity on healthy tissues.
Veloci-Bi is Regeneron’s proprietary bispecific antibody platform. This technology platform enables the generation of full-length bispecific antibodies that resemble natural antibodies, allowing for manufacturing using standard antibody production technologies and exhibiting pharmacokinetic properties similar to those of conventional antibodies.“Cancer treatment urgently requires innovative approaches. Through this expanded collaboration with CytomX, we are advancing the most promising directions in bispecific therapy. Our expertise in oncology is highly complementary to that of CytomX—including the application of our proprietary VelociSuite® technology to accelerate drug discovery and development—making us uniquely ideal partners to jointly pursue this endeavor and deliver new therapies to patients in urgent need of novel medicines.”John Lin, M.D., Ph.D., Senior Vice President of Oncology and Antibody Technology Research at Regeneron, stated。“Our ongoing research collaboration with Regeneron is built on our shared commitment to cutting-edge science and a common vision to push the boundaries of cancer immunotherapy. At CytomX, we are leveraging our deep understanding of masking technologies and protease biology to unlock new opportunities uniquely enabled by our technology,”Sean McCarthy, Ph.D., Chief Executive Officer and Chairman of CytomX Therapeutics, Inc., stated"Regeneron’s deep expertise in the field of bispecific immunotherapies makes it an ideal partner for expanding the application scope of the PROBODY platform. We look forward to building on the strong momentum of our alliance collaboration to continue moving forward, jointly bringing meaningful change to cancer patients."Reference: Company Announcement
Copyright Statement: This article is reprinted from# The Era of Biologics, such asMedia outlets or individuals who do not wish their content to be reposted may contact us, and we will remove it immediately.
